Clinical

Zanubrutinib is a second-generation Bruton tyrosine kinase (BTK) inhibitor that has fewer off-target effects and less cardiotoxicity than ibrutinib, a first-generation BTK inhibitor.

The data published in Scientific Reports are the first to implicate a role for RASGRP4 mutations in B-cell malignancies.

The trastuzumab biosimilar Herzuma was shown to have similar clinical efficacy and safety to the reference product in patients with HER2-positive advanced gastric cancer.

A model developed by researchers in China could help identify patients with non–small cell lung cancer (NSCLC) most likely to benefit from anti– programmed death-ligand 1 (PD-L1) immunotherapy.

An analysis conducted in Japan among patients with acute decompensated heart failure (HF) revealed excessive polypharmacy at hospital discharge is associated with an increased risk of mortality after 1 year.

With no existing respiratory syncytial virus (RSV) vaccine yet, researchers found that a vaccine comparable with the influenza vaccine could prevent tens of thousands of hospitalizations and deaths per year.

Merck had previously received accelerated approval for pembrolizumab for patients with advanced hepatocellular carcinoma (HCC); an FDA panel left the approval in place while waiting on results from KEYNOTE-394.

Natural killer cell therapy CYNK-101 was granted fast track designation by the FDA to treat HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with standard chemotherapy, trastuzumab, and pembrolizumab.

An abstract presented at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition assessed real-world data on patients with multiple myeloma to provide insight into longitudinal testing patterns and rates of sustained minimal residual disease (MRD) negativity.

The panel closes the program with giving their final thoughts on individualizing therapies for plaque psoriasis and metabolic syndrome in specific patient subpopulations.

The report suggests remission and disease activity state alone are not the most important risk factors in pregnant women with well-controlled systemic lupus erythematosus.

Evidence suggests higher levels of iron in pulmonary macrophages heightens the risk of infectious exacerbations.

Drs Lebwohl and Groves list support services to help with patient adherence.

Bhavesh Shah, PharmD, explains how lower volume agents can be beneficial when treating plaque psoriasis and metabolic syndrome.

Investigators identified potential markers of chemotherapy efficacy in patients with non–small cell lung cancer.

Can daratumumab be taken safely as a maintenance therapy? Will quadruplet therapy become more common in the treatment of newly diagnosed multiple myeloma (NDMM)?

An abstract presented at the 63rd American Society of Hematology Meeting & Exposition found that the regimen was effective and that MRD could potentially be used as a biomarker to inform treatment duration.

An indirect assessment of the functioning of smooth muscle activity in the airways and gastrointestinal wall may help explain the shared pathophysiology that links these 2 common childhood ailments.

Outside of survival motor neuron (SMN) treatment, there are several alternatives used in cases where SMN approaches are not appropriate for treating spinal muscular atrophy (SMA).

The research suggests a computed tomography-readable biomarker could help clinicians better understand individual cases of chronic obstructive pulmonary disease.

Self-reported experiences among the patients showed that 76% of patients were extremely or very satisfied with their surgery and 58% of patients were satisfied with the appearance of their healed wound, despite a recurrence rate of 41%.

The eosinophilic esophagitis responded to treatment or resolved after the peanut oral immunotherapy stopped.

An increase in the use of comprehensive genomic profiling among patients with advanced non–small cell lung cancer (NSCLC) was associated with additional life-years gained and a low-cost budget impact.

A new review explored using partial tandem duplication levels from the MLL gene to monitor for minimal residual disease (MRD) status to predict disease relapse following allogeneic hematopoietic stem cell transplant.

New research identified risk factors for postoperative migraine and compared the incidence of migraine following general or neuraxial anesthesia.